Ireland· IE-PA-EU/1/21/1594/001
Rybrevant 350 mg concentrate for solution for infusion
A amivantamab product containing amivantamab, registered in Ireland by Janssen-Cilag International NV. The same ATC class is registered in 15 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Amivantamab is registered in 15 of 19 countries.
Countries holding a registration under ATC L01FX18 (amivantamab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Amivantamab · ATC L01FX18
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amivantamab costs, country by country.
Normalised to the WHO defined daily dose (75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Amivantamab · price per daily dose (75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$335.64
The record
At a glance
HPRA (Ireland)- Active substance
- Amivantamab
- Manufacturer
- Janssen-Cilag International NV
- Country
- Ireland (IE)
- ATC code
- L01FX18
- ATC class
- Amivantamab
- Defined daily dose
- 75 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/21/1594/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Amivantamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRybrevant 350 mgJanssen-Cilag International
- CzechiaRYBREVANTJanssen-Cilag International N.V., Beerse
- FinlandRybrevantJanssen-Cilag International NV
- IcelandRybrevantJanssen-Cilag International NV*
- PolandRybrevantJanssen-Cilag International N.V.
- SwedenRybrevant 350 mg Koncentrat till infusionsvätska, lösningJanssen-Cilag International NV
- NorwayRybrevantJanssen-Cilag International N.V.
- NetherlandsRybrevant 1600 mg, oplossing voor injectieJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rybrevant
- Liechtenstein · Rybrevant
- Norway · Rybrevant
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/27bf5083-1962-465a-b7a3-768e6c9e87e9 GET /v1/drugs/27bf5083-1962-465a-b7a3-768e6c9e87e9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01FX18"
],
"strength": null,
"pa_number": "EU/1/21/1594/001",
"substances": [
"Amivantamab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "09/12/2021",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about amivantamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.